Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Neoplasm Metastasis
Interventions: DRUG: Trastuzumab|DRUG: RAD001
Sponsor: M.D. Anderson Cancer Center
Collaborators: Novartis